News | Heart Valve Technology

Keystone Heart Ltd. announced that data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium demonstrate an increase in brain lesions for patients following transcatheter aortic valve replacement (TAVR) procedures, which were significantly associated with delirium.

Home November 07, 2016
Home
News | Stents

November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT) ...

Home November 07, 2016
Home
News | Heart Valve Technology

November 7, 2016 – A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device ...

Home November 07, 2016
Home
News | Stents

November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high ...

Home November 07, 2016
Home
News | Stents Bioresorbable

The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C., featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients.

Home November 07, 2016
Home
News | Stents

November 7, 2016 – The large multinational randomized BIONICS study found that a novel elastic polymer coated ...

Home November 07, 2016
Home
News | Cath Lab

November 7, 2016 – Two-year results from the COLOR Trial, the first large-scale multicenter prospective study of its ...

Home November 07, 2016
Home
Feature | Dave Fornell

November 4, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional ...

Home November 04, 2016
Home
News | Cardiovascular Surgery

Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic–Baltic–British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.

Home November 03, 2016
Home
News | Structural Heart Occluders

St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

Home November 02, 2016
Home
News | Stents Drug Eluting

Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers analysis to compare the safety and efficacy of biodegradable polymer stents (BP-DES) to the durable polymer Resolute Integrity drug-eluting stent (DP-DES) from Medtronic. At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity.

Home November 02, 2016
Home
News | Heart Valve Technology

Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early feasibility study, showing improved hemodynamics from baseline and consistent valve performance at one year. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, the positive new data from the first-of-its-kind early feasibility study led the U.S. Food and Drug Administration (FDA) to also recently approve the initiation of a Pivotal Investigational Device Exemption (IDE) study to evaluate the valve’s safety and effectiveness.

Home November 02, 2016
Home
Technology | Structural Heart Occluders

St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the Amplatzer PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO). With the approval, patients in the United States with a PFO (a small opening between the upper chambers of the heart) who have suffered an ischemic stroke — a stroke resulting from blockages in the blood supply to the brain — will now have access to a closure device proven to reduce their risk of recurrent stroke, rather than relying on medical management alone.

Home November 02, 2016
Home
News | PET-CT

Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission tomography (PET)/computed tomography (CT) activity-based probe to detect atherosclerotic plaques. The study is published in the October issue of The Journal of Nuclear Medicine.

Home November 01, 2016
Home
News | Stents Drug Eluting

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the ...

Home November 01, 2016
Home
Subscribe Now